These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38845625)

  • 21. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
    Harada K; Toriyabe K; Ono S
    J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China.
    Peng F; Zheng H
    Ther Innov Regul Sci; 2023 Nov; 57(6):1314-1321. PubMed ID: 37651044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements.
    Lee B; Bae EY; Bae S; Choi HJ; Son KB; Lee YS; Jang S; Lee TJ
    BMC Health Serv Res; 2021 Sep; 21(1):967. PubMed ID: 34521408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Intractable Rare Dis Res; 2012 Feb; 1(1):3-9. PubMed ID: 25343064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.
    Heemstra HE; Giezen TJ; Mantel-Teeuwisse AK; de Vrueh RL; Leufkens HG
    Drug Saf; 2010 Feb; 33(2):127-37. PubMed ID: 20082539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases.
    Enya K; Lim Y; Sengoku S; Kodama K
    Drug Discov Today; 2023 Oct; 28(10):103755. PubMed ID: 37648019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
    Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
    Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical development and marketing application review times for novel orphan-designated drugs.
    Demirci E; Knicley J; Fiorentino L
    Front Med (Lausanne); 2024; 11():1404922. PubMed ID: 38903827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric Orphan Drug Indications: 2010-2018.
    Kimmel L; Conti RM; Volerman A; Chua KP
    Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of orphan drug approval in the European Union.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Eur J Clin Pharmacol; 2008 May; 64(5):545-52. PubMed ID: 18210097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West.
    Okabayashi S; Kobayashi T; Hibi T
    Inflamm Intest Dis; 2018 Nov; 3(1):25-31. PubMed ID: 30505839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of drugs approved in Japan without conducting confirmatory clinical trials.
    Izuka S; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2021 Dec; 46(6):1582-1590. PubMed ID: 34250620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T; Jürges H; Michaeli DT
    BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerating the integration of China into the global development of innovative anticancer drugs.
    Huang H; Wu D; Miao H; Tang Y; Liu C; Fang H; Meng X; Wang S; Zhu Q; Wang X; Du J; Yang Z; Li N; Xu B; He J
    Lancet Oncol; 2022 Nov; 23(11):e515-e520. PubMed ID: 36328025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New opportunity for orphan drug development in Japan: Early exploratory clinical trial bases promote drug translation from basic studies to clinical application.
    Song P; Gao J; Kokudo N; Tang W
    Intractable Rare Dis Res; 2012 May; 1(2):95-7. PubMed ID: 25343079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.